SINOPHARM GROUP 1/5/O.N. (X2S1) — Net Asset Quality Index
SINOPHARM GROUP 1/5/O.N. (X2S1) has a Net Asset Quality Index of 34.4% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €390.36 Billion minus total liabilities of €256.20 Billion yields net assets of €134.16 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See how many days can SINOPHARM GROUP 1/5/O.N. fund operations to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
SINOPHARM GROUP 1/5/O.N. Net Asset Quality Index Over Time (2021–2025)
This chart shows how SINOPHARM GROUP 1/5/O.N.'s Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 34.4%, representing net assets of €134.16 Billion against total assets of €390.36 Billion EUR. Explore SINOPHARM GROUP 1/5/O.N. cash conversion from operations to assess how effectively this company generates cash.
Annual Net Asset Quality Index for SINOPHARM GROUP 1/5/O.N. (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for SINOPHARM GROUP 1/5/O.N. from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see SINOPHARM GROUP 1/5/O.N. (X2S1) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 34.4% | €134.16 Billion | €390.36 Billion | €256.20 Billion | ▲ +2.1 pp |
| 2024 | 32.2% | €126.69 Billion | €392.83 Billion | €266.14 Billion | ▲ +0.9 pp |
| 2023 | 31.4% | €120.32 Billion | €383.39 Billion | €263.08 Billion | ▲ +1.2 pp |
| 2022 | 30.2% | €110.07 Billion | €364.78 Billion | €254.71 Billion | ▲ +0.5 pp |
| 2021 | 29.7% | €99.65 Billion | €335.41 Billion | €235.76 Billion | — |